152 related articles for article (PubMed ID: 32542318)
21. Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study.
Hepel JT; Leonard KL; Safran H; Ng T; Taber A; Khurshid H; Birnbaum A; ; Wazer DE; DiPetrillo T
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1021-1027. PubMed ID: 27745983
[TBL] [Abstract][Full Text] [Related]
22. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non-Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution.
Abreu CECV; Moraes FY; Miranda FA; Siqueira GSM; Gadia R; Haddad CK; Carvalho HA
J Glob Oncol; 2018 Jul; 4():1-8. PubMed ID: 30085881
[TBL] [Abstract][Full Text] [Related]
24. Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer.
Tembhekar AR; Wright CL; Daly ME
Clin Lung Cancer; 2017 May; 18(3):293-298. PubMed ID: 28089158
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer.
Eriguchi T; Takeda A; Sanuki N; Tsurugai Y; Aoki Y; Oku Y; Hara Y; Akiba T; Shigematsu N
Lung Cancer; 2017 Jul; 109():62-67. PubMed ID: 28577952
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer.
Nantavithya C; Gomez DR; Wei X; Komaki R; Liao Z; Lin SH; Jeter M; Nguyen QN; Li H; Zhang X; Poenisch F; Zhu XR; Balter PA; Feng L; Choi NC; Mohan R; Chang JY
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):558-563. PubMed ID: 29680255
[TBL] [Abstract][Full Text] [Related]
27. Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery.
Varlotto J; Fakiris A; Flickinger J; Medford-Davis L; Liss A; Shelkey J; Belani C; DeLuca J; Recht A; Maheshwari N; Barriger R; Yao N; DeCamp M
Cancer; 2013 Aug; 119(15):2683-91. PubMed ID: 23605504
[TBL] [Abstract][Full Text] [Related]
28. Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy.
Liu J; Hui C; Ladbury C; Waddington T; Erhunmwunsee L; Raz D; Kim J; Salgia R; Chenery S; Pearlstein D; Schwer A; Amini A
Clin Lung Cancer; 2021 Sep; 22(5):e678-e683. PubMed ID: 33712362
[TBL] [Abstract][Full Text] [Related]
29. A SUV
Ye L; Xu F; Shi S; Zeng Z; Jin X; Huang Y; Lu C; Gu J; Ge D; He J
Clin Transl Oncol; 2018 Aug; 20(8):1026-1034. PubMed ID: 29327241
[TBL] [Abstract][Full Text] [Related]
30. Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
Yamamoto T; Kadoya N; Shirata Y; Kaneta T; Koto M; Umezawa R; Ishikawa Y; Kubozono M; Sugawara T; Matsushita H; Abe K; Takeda K; Jingu K
Ann Nucl Med; 2015 Oct; 29(8):666-73. PubMed ID: 26040413
[TBL] [Abstract][Full Text] [Related]
31. Should stereotactic body radiotherapy doses be adjusted according to tumor size in early-stage non-small-cell lung cancer? A systematic review and meta-analysis.
Luo H; Cui Y; Song H; Mao R; Gao Q; Ge H
Future Oncol; 2019 Sep; 15(26):3071-3079. PubMed ID: 31426674
[No Abstract] [Full Text] [Related]
32. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer.
Haque W; Verma V; Polamraju P; Farach A; Butler EB; Teh BS
Radiother Oncol; 2018 Nov; 129(2):264-269. PubMed ID: 30031630
[TBL] [Abstract][Full Text] [Related]
33. Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy.
Hörner-Rieber J; Bernhardt D; Dern J; König L; Adeberg S; Paul A; Heussel CP; Kappes J; Hoffmann H; Herth FJP; Debus J; Warth A; Rieken S
Radiother Oncol; 2017 Nov; 125(2):317-324. PubMed ID: 28919006
[TBL] [Abstract][Full Text] [Related]
34. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
[TBL] [Abstract][Full Text] [Related]
35. Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry.
Singh R; Ansinelli H; Sharma D; Jenkins J; Davis J; Vargo JA; Sharma S
Am J Clin Oncol; 2019 Jul; 42(7):602-606. PubMed ID: 31232723
[TBL] [Abstract][Full Text] [Related]
36. Image-based management of empiric lung stereotactic body radiotherapy (SBRT) without biopsy: Predictors from a 10-year single institution experience.
Hasan S; Colonias A; Mickus T; VanDeusen M; Wegner RE
Thorac Cancer; 2018 Jun; 9(6):699-706. PubMed ID: 29697204
[TBL] [Abstract][Full Text] [Related]
37. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.
Kann BH; Verma V; Stahl JM; Ross R; Dosoretz AP; Shafman TD; Gross CP; Park HS; Yu JB; Decker RH
Radiother Oncol; 2019 May; 134():44-49. PubMed ID: 31005223
[TBL] [Abstract][Full Text] [Related]
38. Prognositc significance of SUV
Dong M; Liu J; Sun X; Xing L
J Med Imaging Radiat Oncol; 2017 Oct; 61(5):652-659. PubMed ID: 28266166
[TBL] [Abstract][Full Text] [Related]
39. Never too old: A single-institution experience of stereotactic body radiation therapy for patients 90 years and older with early stage lung cancer.
Videtic GMM; Woody NM; Reddy CA; Stephans KL
Pract Radiat Oncol; 2017; 7(6):e543-e549. PubMed ID: 28867545
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy.
Tanaka H; Hayashi S; Hoshi H
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e113-7. PubMed ID: 24176011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
